1-(1-methoxycyclopentyl)methanamine | 326487-80-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(1-methoxycyclopentyl)methanamine
• 英文别名: (1-Methoxycyclopentyl)methanamine
• CAS: 326487-80-3
• 化学式: C₇H₁₅NO
• 分子量: 129.202
• InChiKey: VVTJJJIVABEZIO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(2-cyclopropyl-6-(6-formyl-1-oxoisoindolin-2-yl)pyridin-4-yl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)benzonitrile 、 1-(1-methoxycyclopentyl)methanamine 在 N,N-二异丙基乙胺 、 甲醇 、 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 以11.6 mg的产率得到4-{2-cyclopropyl-6-[6-({[(1-methoxycyclopentyl)methyl]amino}methyl)-1-oxo-3H-isoindol-2-yl]pyridin-4-yl}-3-(4-methyl-1,2,4-triazol-3-yl)benzonitrile
  参考文献：
  名称：

  [EN] CBL-B MODULATORS AND USES THEREOF
  [FR] MODULATEURS DE CBL-B ET LEURS UTILISATIONS

  摘要：

  本发明提供了化合物、其组合物以及使用它们的方法，用于抑制Cbl-b和治疗Cbl-b介导的疾病。

  公开号：

  WO2022217276A1

文献信息

• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSÉS ORGANIQUES
  申请人：NOVARTIS AG

  公开号：WO2005051895A1

  公开（公告）日：2005-06-09

  Disclosed are δ-amino-Ϝ-hydroxy-ω-aryl-alkanoic acid amide compounds of formula (I) and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.

  揭示了具有抑制肾素作用的δ-氨基-Ϝ-羟基-ω-芳基-烷酸酰胺化合物的化学式(I)及其盐。还揭示了包含这些化合物的药物组合物以及用于治疗高血压、动脉粥样硬化、不稳定性冠状动脉综合征、充血性心力衰竭、心肌肥大、心脏纤维化、心肌病后梗死、不稳定性冠状动脉综合征、舒张功能障碍、慢性肾脏疾病、肝纤维化、糖尿病引起的并发症（如肾病、血管病和神经病变）、冠状动脉疾病、血管成形术后再狭窄、眼内压升高、青光眼、异常血管生长、高醛固酮症、认知障碍、阿尔茨海默病、痴呆、焦虑状态和认知障碍的治疗方法。
• Organic compounds
  申请人：Baeschlin Kaspar Daniel

  公开号：US20070135498A1

  公开（公告）日：2007-06-14

  Disclosed are δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amide compounds of formula (I) and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.

  本发明涉及一种具有肾素抑制作用的δ-氨基-γ-羟基-ω-芳基-脂肪酸酰胺化合物(I)及其盐。还公开了包含这些化合物的制药组合物以及用于治疗高血压、动脉粥样硬化、不稳定性冠状动脉综合征、充血性心力衰竭、心脏肥大、心脏纤维化、心肌梗死后的心肌病、舒张功能障碍、慢性肾脏病、肝纤维化、糖尿病引起的并发症（如肾病、血管病和神经病）、冠状血管疾病、血管成形术后再狭窄、眼内压增高、青光眼、异常血管生长、高醛固酮症、认知障碍、老年痴呆症、焦虑状态和认知障碍的治疗方法。
• ORGANIC COMPOUNDS
  申请人：Baeschlin Daniel Kaspar

  公开号：US20090253703A1

  公开（公告）日：2009-10-08

  Disclosed are δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amide compounds of formula (I) and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.

  本发明公开了式(I)的δ-氨基-γ-羟基-ω-芳基-脂肪酸酰胺化合物及其盐，具有抑制肾素的特性。本发明还公开了包含这些化合物的药物组合物和治疗高血压、动脉粥样硬化、不稳定性冠状动脉综合症、充血性心力衰竭、心脏肥大、心脏纤维化、心肌梗死后心肌病、舒张功能障碍、慢性肾脏病、肝纤维化、糖尿病引起的并发症，如肾病、血管病和神经病变、冠状动脉疾病、血管成形术后再狭窄、眼内压升高、青光眼、异常血管生长、高醛固酮症、认知障碍、阿尔茨海默病、痴呆、焦虑状态和认知障碍的治疗方法。
• US7582782B2
  申请人：——

  公开号：US7582782B2

  公开（公告）日：2009-09-01
• US7851642B2
  申请人：——

  公开号：US7851642B2

  公开（公告）日：2010-12-14